natgillin/translations-raw huggingface dataset:
Following infusion, peak concentrations of VWF markers (VWF:RCo, VWF:Ag, and VWF:CB) and FVIII:C were achieved immediately with a mean IR of 0.013-0.016 (IU/mL)/(IU/kg) for VWF markers and 0.017-0.021 (IU/mL)/(IU/kg) for FVIII:C. The elimination t1/2 of VWF markers was between 9.7 and 12.9 h whereas FVIII:C had a longer t1/2 of approximately 18 h due to a plateau effect that may represent the net effect of decreasing levels of exogenous FVIII, combined with increasing endogenous FVIII levels.
Po infundiranju so bile takoj dosežene najvišje koncentracije VMF markerjev v plazmi (VWF:RCo, VWF:Ag in VWF:CB) in FVIII:C pri srednji hitrosti infundiranja 0,013-0,016 (i.e./ml)/(i.e./kg) za VWF markerje in 0,017-0,021 (i.e./ml)/(i.e./kg) za FVIII:C. Razpolovni čas izločanja (t ½) za VWF markerje je bil med 9,7 in 12,9 ur, pri čemer je bil t ½ za FVIII:C daljši in je znašal približno 18 ur zaradi plato učinka, kar lahko predstavlja neto učinek zmanjšanih ravni eksogeno uporabljenega FVIII, v kombinaciji s povečanjem ravni endogeno uporabljenega FVIII.
Following inhalation of Brimica Genuair 340/12 micrograms, aclidinium and formoterol showed terminal elimination half-lives of approximately 5 h and 8 h, respectively.
Končni razpolovni čas izločanja po inhalaciji zdravila Brimica Genuair 340/12 mikrogramov znaša približno 5 ur za aklidinij in 8 ur za formoterol.
Following inhalation of Duaklir Genuair 340/12 micrograms, aclidinium and formoterol showed terminal elimination half-lives of approximately 5 h and 8 h, respectively.
Končni razpolovni čas izločanja po inhalaciji zdravila Duaklir Genuair 340/12 mikrogramov znaša približno 5 ur za aklidinij in 8 ur za formoterol.
Following inhalation of these doses with the Breelib the maximum plasma concentrations (Cmax) and systemic exposures (AUC (0– tlast)) increased dose-proportionally.
Po inhalaciji teh odmerkov z nebulatorjem Breelib so opazili, da so največje plazemske koncentracije (Cmax) in sistemska izpostavljenost (AUC (0–tlast)) povečale glede na velikost odmerka.
Following initial doses of rifampicin, a transient increase in ambrisentan AUC(0–τ) (121% and 116% after first and second doses of rifampicin, respectively) was observed, presumably due to a rifampicin-mediated OATP inhibition.
Po začetnih odmerkih rifampicina so ugotovili prehodno povečanje AUC (0-τ) ambrisentana (121 % po prvem in 116 % po drugem odmerku rifampicina), verjetno zaradi zavrtja OATP z rifampicinom.
Following initial therapy, you will receive a standard pack containing 1 bottle of RAVICTI and a reclosable bottle cap adapter.
Po koncu začetnega zdravljenja boste v lekarni prejeli standardni komplet, ki bo vseboval 1 steklenico zdravila RAVICTI in zamašek z nastavkom za brizgo.
Following initiation of therapy, serum creatinine should be measured prior to each dose of Zoledronic acid Actavis and treatment should be withheld if renal function has deteriorated.
Po uvedbi zdravljenja je treba serumski kreatinin izmeriti pred vsakim odmerkom zdravila Zoledronska kislina Actavis in zdravljenje prekiniti, če se delovanje ledvic poslabša.
Following initiation of treatment, additional CE marked oral syringes compatible with the reclosable bottle cap adapter can be obtained from a pharmacy.
Po uvedbi zdravljenja so dodatne peroralne brizge z oznako CE, združljive z zamaški z nastavkom za brizgo, na voljo v lekarni
Following initiation of treatment, the pharmacy will provide a standard pack containing the medicinal product and reclosable bottle cap adapter.
Po uvedbi zdravljenja boste v lekarni prejeli standardno pakiranje, ki bo vsebovalo zdravilo in zamašek z nastavkom za brizgo.
Following injection, pigs may have an increased rectal temperature of about 1.4 °C for up to two days, and in some pigs of up to 2.5 °C, but this should not last more than 24 hours after the injection.
Po injiciranju se lahko prašičem do dva dni zviša rektalna temperatura za 1,4 °C, nekaterim prašičem pa za največ 2,5 °C, vendar to ne bi smelo trajati več kot 24 ur po injiciranju.
Following intramuscular injection of single doses (25-150 mg) in the deltoid muscle, on average, a 28% higher Cmax was observed compared with injection in the gluteal muscle.
Po intramuskularnem injiciranju enkratnih odmerkov (25-150 mg) v deltoidno mišico so v povprečju opazili za 28% večjo vrednost Cmax kot pri injiciranju v glutealno mišico.
Following intrathecal administration of DepoCyte, serious central nervous system toxicity, including persistent convulsions (7%), extreme somnolence (3%), hemiplegia (1%), visual disturbances including blindness (1%), deafness (3%) and cranial nerve palsies (3%) have been reported.
Po intratekalnem dajanju zdravila DepoCyte so poročali o resnih znakih toksičnosti centralnega živčevja, vključno z dolgotrajnimi konvulzijami (7%), močno somnolenco (3%), hemiplegijo (1%), motnjami vida vključno s slepoto (1%), gluhostjo (3%) ter parezami možganskih živcev (3%).
Following intravenous administration of 14C-radiolabeled regadenoson to rats and dogs, most radioactivity (85-96%) was excreted in the form of unchanged regadenoson.
Po intravenskem dajanju z 14C-označenega regadenozona podganam in psom se je večina radioaktivnosti (85-96%) izločila v obliki nespremenjenega regadenozona.
Following intravenous administration of a 3 mg dose of bazedoxifene alone, the volume of distribution is 14.7 3.9 l/kg.
Po intravenski uporabi 3 mg odmerka samega bazedoksifena je volumen porazdelitve 14,73,9 l/kg.
Following intravenous administration of epoetin alfa in subjects with chronic renal failure, the volume of distribution ranged from 57-107 ml/kg after single dosing (12 IU/kg) to 42– 64 ml/kg after multiple dosing (48–192 IU/kg), respectively.
Po intravenskem dajanju epoetina alfa osebam s kronično ledvično odpovedjo je bil razpon volumna porazdelitve od 57–107 ml/kg po enkratnem odmerjanju (12 i.e./kg) oz. do 42–64 ml/kg po večkratnem odmerjanju (48–192 i.e./kg).
Following intravenous administration of palonosetron 0.25 mg once every other day for 3 doses in 11 testicular cancer patients, the mean ( SD) increase in plasma concentration from Day 1 to Day 5 was 42  34 %.
Po intravenskem dajanju palonosetrona v odmerku 0,25 mg vsak drugi dan je po 3 odmerkih pri 11 bolnikih z rakom mod koncentracija v plazmi od 1. do 5. dne povprečno ( SD) zrasla za 42  34 %.
Following intravenous administration of topotecan at doses of 0.5 to 1.5 mg/m2 as a 30 minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62 l/h (SD 22), corresponding to approximately 2/3 of liver blood flow.
Ugotovili so, da je plazemski očistek topotekana po intravenskem infundiranju v odmerku 0,5 do 1,5 mg/m2 5 zaporednih dni pri času infuzije 30 minut visok, in sicer 62 l/h (SD 22), kar pomeni približno 2/3 pretoka krvi skozi jetra.
Following intravenous administration of topotecan at doses of 0.5 to 1.5 mg/m2 as a 30 minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62 l/h (SD 22), corresponding to approximately 2/3 of liver blood flow.
Ugotovili so, da je plazemski očistek topotekana po intravenskem infundiranju v odmerku 0,5 do 1,5 mg/m2 pet zaporednih dni pri času infuzije 30 minut visok, in sicer 62 l/h (SD 22), kar pomeni približno 2/3 pretoka krvi skozi jetra.
Following intravenous administration of Topotecan, at doses of 0.5 to 1.5 mg/m2 as a 30 minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62 l/h (SD 22), corresponding to approximately 2/3 of liver blood flow.
Po vsakodnevni 30-minutni intravenski infuziji topotekana v odmerkih od 0,5 do 1,5 mg/m2 v času 5 dni je bil njegov plazemski očistek velik, in sicer 62 l/h (SD 22), kar ustreza približno 2/3 pretoka krvi skozi jetra.
Following intravenous administration, an approximate 25% difference between paediatric and adult patients in the area under the curve from time 0 to infinity (AUC[0-∞]) was observed; however, this difference was less than the 2-fold range in AUC(0-∞) observed for the pediatricpatients .
Po intravenski uporabi so med pediatričnimi in odraslimi bolniki ugotovili približno 25 % razliko v površini pod krivuljo od časa 0 do neskončnosti (AUC(0–∞)); vendar je bila ta razlika manjša od 2-kratnega razpona AUC(0–∞), ugotovljenega pri pediatričnih bolnikih.
Following intravenous administration, an approximate 25% difference between paediatric and adult patients in the area under the curve from time 0 to infinity (AUC[0-∞]) was observed; however, this difference was less than the 2-fold range in AUC(0-∞) observed for the pediatricpatients.
Po intravenski uporabi so med pediatričnimi in odraslimi bolniki ugotovili približno 25 % razliko v površini pod krivuljo od časa 0 do neskončnosti (AUC(0–∞)); vendar je bila ta razlika manjša od 2-kratnega razpona AUC(0–∞), ugotovljenega pri pediatričnih bolnikih.
Following intravenous administration, approximately 58% of the administered radiolabelled dose (or 73% of the recovered radioactivity) was excreted in faeces by 192 hours post-dose.
Po intravenski uporabi se je približno 58 % uporabljenega radioaktivno označenega odmerka (oziroma 73 % najdene radioaktivnosti) pojavilo v blatu do 192 ur po odmerku.
Following intravenous administration, at the beginning most organs contained an amount of radioactivity which represented their content of 64Cu-laden blood.
Po intravenskem dajanju je na začetku večina organov vsebovala količino radioaktivnosti, enako njihovi vsebnosti bakra (64Cu) v krvi.
Following intravenous administration, choriogonadotropin alfa is distributed to the extracellular fluid space with a distribution halflife of around 4.5 hours.
Po intravenski uporabi se horiogonadotropin alfa porazdeli v zunajceličnem prostoru s porazdelitvenim razpolovnim časom približno 4,5 ure.
Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of about one day.
Po intravenskem dajanju, se folitropin alfa porazdeli v zunajcelični prostor z začetnim razpolovnim časom približno 2 uri in izloči iz telesa s končnim razpolovnim časom približno en dan.
Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of about one day.
Po intravenski uporabi se folitropin alfa porazdeli v zunajcelični prostor z začetnim razpolovnim časom približno 2 uri in izloči iz telesa s končnim razpolovnim časom približno en dan.
Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of about one day.
Po intravenski uporabi se folitropin alfa porazdeli v zunajcelični prostor z začetnim razpolovnim časom približno dve uri in izloči iz telesa s končnim razpolovnim časom približno en dan.
Following intravenous administration, lutropin alfa is rapidly distributed with an initial half-life of approximately one hour and eliminated from the body with a terminal half-life of about 10-12 hours.
Po intravenskem dajanju se lutropin alfa hitro porazdeli z začetnim razpolovnim časom približno 1 uro in se izloči iz telesa s končnim razpolovnim časom približno 10–12 ur.
Following intravenous administration, naloxone is rapidly distributed (distribution half- life ~ 4 minutes).
Po intravenski administraciji se nalokson hitro porazdeli (porazdelitveni razpolovni čas ~ 4 minute).
Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.62 L/h (about 30 % of total clearance).
Po intravenski uporabi je plazemski očistek valsartana okrog 2 l/uro, njegov ledvični očistek pa je 0,62 l/uro (okrog 30% celotnega očistka).
Following intravenous bolus administration of a 1.0 mg/m2 and 1.3 mg/m2 dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively.
Po intravenski aplikaciji bolusnega odmerka 1,0 mg/m2 in 1,3 mg/m2 11 bolnikom z diseminiranim plazmocitomom in očistkom kreatinina večjim kot 50 ml/min, sta bili povprečni vrednosti najvišjih plazemskih koncentracij bortezomiba po prvem odmerku 57 in 112 ng/ml.
Following intravenous bolus administration of a 1.0 mg/m2 and 1.3 mg/m2 dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively.
Po intravenski aplikaciji bolusnega odmerka 1,0 mg/m2 in 1,3 mg/m2 11 bolnikom z diseminiranim plazmocitomom in očistkom kreatinina, večjim kot 50 ml/min, sta bili povprečni vrednosti najvišjih plazemskih koncentracij bortezomiba po prvem odmerku 57 in 112 ng/ml.
Following intravenous bolus injection of 10 + 10 U in patients with acute myocardial infarction reteplase antigen is distributed in plasma with a dominant half-life (t1/2) of 185 min and eliminated with a terminal half-life (t1/2ß) of 5.5 hours12.5 min at a clearance rate of 12125 ml/min.
Po intravenskem bolusnem injiciranju 10 + 10 enot bolnikom z akutnim miokardnim infarktom se antigen reteplaze v plazmi porazdeljuje s prevladujočim razpolovnim časom (t1/2α) 18  5 minut in se izloča s končnim razpolovnim časom (t1/2ß) 5,5 ur  12,5 minut in očistkom 121  25 ml/minuto.
Following intravenous dosing the volume of distribution at steady-state (Vss) was 31.7 l/kg.
Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenoznem odmerjnaju je 31,7 L/kg.
Following intravenous infusion, the apparent steady-state volume of distribution was 0.6 to 0.8 l/kg in healthy subjects.
Po intravenski infuziji je bil volumen porazdelitve v stanju dinamičnega ravnovesja pri zdravih osebah 0,6 do 0,8 l/kg.
Following intravnous bolus administration of 30 mg tenecteplase in patients with acute myocardial infarction, the initially estimated tenecteplase plasma concentration was 6.45 ± 3.60 µg/mL (mean ± SD) .
Po intravenskem bolusu 30 mg tenekteplaze je bila pri bolnikih z akutnim miokardnim infarktom začetna ocena koncentracije tenekteplaze v plazmi 6,45 ± 3,60 µg/ml (srednja vrednost ± SD).
Following intra­arterial injection of liraglutide to rabbits, slight to moderate haemorrhage, erythema and swelling at the injection site were observed.
Pri zajcih se je po intraarterijskem injiciranju liraglutida pojavila rahla do zmerna krvavitev, eritem in otekanje na mestu injiciranja.
Following long-term treatment, fentanyl may cause withdrawal in the new-born infant.
Po dolgotrajnem zdravljenju lahko fentanil povzroči odtegnitvene simptome pri novorojencih.
Following marketing, bullous eruption has been reported rarely in this population.
V okviru postmarketinških izkušenj so pri tej populaciji poročali o redkih primerih z buloznim izpuščajem.
Following metaphylactic use, approximately 86% of the healthy animals remained free of clinical signs of disease (as compared to approximately 65% of animals in the untreated control group).
Po metafilaktični uporabi je približno 86 % zdravih živali ostalo brez kliničnih znakov bolezni (v primerjavi s približno 65 % živali v nezdravljeni kontrolni skupini.
Following monthly administration of darbepoetin alfa, at subcutaneous doses ranging from 0.6 to 2.1 µg/kg, the terminal half-life was
Po uporabi darbepoetina alfa enkrat na mesec v subkutanih odmerkih od 0,6 do
Following monthly administration of darbepoetin alfa, at subcutaneous doses ranging from 0.6 to 2.1 µg/kg, the terminal half-life was
Po uporabi darbepoetina alfa enkrat na mesec v subkutanih odmerkih od 0,6 do 2,1
Following monthly administration of darbepoetin alfa, at subcutaneous doses ranging from 0.6 to 2.1 µg/kg, the terminal half-life was 73 hours (SD 24).
Po uporabi darbepoetina alfa enkrat na mesec v subkutanih odmerkih od 0,6 do 2,1
Following multiple doses of CE 0.45 mg/bazedoxifene 20 mg, the mean steady state pharmacokinetic parameters for CE and bazedoxifene (baseline adjusted for total estrone) are summarised below.
Povprečni farmakokinetični parametri CE in bazedoksifena v stanju dinamičnega ravnovesja po večkratnih odmerkih 0,45 mg CE/20 mg bazedoksifena (izhodiščne vrednosti so bile prilagojene glede na skupni estron) so povzeti v preglednici spodaj.
Following multiple doses of lumacaftor/ivacaftor for 10 days, subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had higher exposures (AUC0-12hr by approximately 50% and Cmax by approximately 30%) compared with healthy subjects matched for demographics.
Po večkratnih odmerkih lumakaftorja/ivakaftorja, ki so jih prejemali 10 dni, so imele osebe z zmerno okvarjeno funkcijo jeter (razred B po Child-Pughovi lestvici, rezultat 7 do 9) večje izpostavljenosti (AUC0-12h za približno 50 % in Cmax za približno 30 %) kot zdrave osebe z enakimi demografskimi podatki.
Following multiple monthly doses, pasireotide intramuscular use demonstrates approximately dose-proportional pharmacokinetic exposures in the dose range of 20 mg to 60 mg every 4 weeks in patients with acromegaly.
Pri bolnikih z akromegalijo je po več mesečnih odmerkih farmakokinetična izpostavljenost pasireotidu za intramuskularno uporabo približno sorazmerna z višino odmerka v okviru odmerjanja od 20 mg do 60 mg vsake 4 tedne.
Following multiple once-daily doses of 20 mg to healthy subjects in the fasted state, maximum plasma concentrations of rimonabant are achieved in approximately 2 hours with steady state plasma levels achieved within 13 days (Cmax = 196 ±
Po večkratni uporabi 20 mg enkrat na dan na tešče pri zdravih preiskovancih doseže rimonabant največjo plazemsko koncentracijo v približno 2 urah, plazemsko koncentracijo v stanju dinamičnega ravnovesja pa v 13 dneh (Cmax = 196 ± 28,1 ng/ml;
Following multiple oral doses of abacavir 300 mg twice a day there is no significant accumulation of abacavir.
Po večkratnem peroralnem odmerku po 300 mg dvakrat dnevno se abakavir znatno ne akumulira.
Following multiple oral doses of daclatasvir 60 mg once daily in combination with peginterferon alfa and ribavirin in treatment-naïve patients with genotype 1 chronic HCV, the geometric mean (CV%) daclatasvir Cmax was 1534 (58) ng/ml, AUC0-24h was 14122 (70) ngh/ml, and Cmin was 232 (83) ng/ml.
Pri ponavljajočih se peroralnih odmerkih daklatasvirja v odmerku 60 mg enkrat na dan v kombinaciji s peginterferonom alfa in ribavirinom pri predhodno nezdravljenih bolnikih s kronično okužbo z genotipom 1 HCV so bile geometrijske srednje (KV %) vrednosti daklatasvirja naslednje: vrednost Cmax 1.534 (58) ng/ml, vrednost AUC0-24h 14.122 (70) ngh/ml, vrednosti Cmin pa 232 (83) ng/ml.
Following multiple-dose oral administration of lamivudine 300 mg once daily for seven days, the mean (CV) steady-state Cmax is 2.04 µg/ml (26%) and the mean (CV) AUC24 is 8.87 µg.h/ml (21%).
Po peroralnem sedemdnevnem dajanju lamivudina v odmerku 300 mg enkrat dnevno znaša srednja Cmax v stanju dinamičnega ravnovesja 2,04 µg/ml (26 %), srednja (CV) AUC24 pa 8,87 µg.h/ml (21 %).
Following once-daily administration of DuoTrav PQ in healthy subjects (N=22) for 5 days, travoprost free acid was not quantifiable in plasma samples from the majority of subjects (94.4%) and generally was not detectable one hour after dosing. .
Po odmerjanju zdravila DuoTrav (konzerviranega s polikvaternijem-1) enkrat na dan pri zdravih preiskovancih (N=22) v času 5 dni ni bilo mogoče določiti količine proste kisline travoprosta v vzorcih plazme večine preiskovancev (94,4%) in ga v splošnem ni bilo mogoče najti eno uro po odmerjanju.
Following one-hour IT administration (1 – 10 μg), both cumulative exposure (AUC; range: 83.6 – 608 ng/h/ml) and peak exposure (Cmax; range: 16.4 – 132 ng/ml) values were variable and dose-dependent, but appeared only approximately dose-proportional.
Po enourni intratekalni aplikaciji (1–10 µg) sta bili kumulativna izpostavljenost (AUC; razpon 83,6– 608 ng/h/ml) in največja izpostavljenost (Cmax ; razpon 16,4 - 132 ng/ml) spremenljivi in odvisni od velikosti odmerka, vendar le delno proporcionalni velikosti odmerka.
Following oral administration in healthy volunteers, the elimination half-lives of sunitinib and its primary active desethyl metabolite are approximately 40 – 60 hours, and 80 – 110 hours, respectively.
Razpolovni čas izločanja sunitiniba po peroralni uporabi pri zdravih prostovoljcih je približno 40-60 ur, njegovega primarnega aktivnega desetil-presnovka pa približno 80-110 ur.
Following oral administration in healthy volunteers, the t½ was approximately 18 h, suggesting that once-daily dosing is appropriate.
Po peroralnem dajanju zdravim prostovoljcem je bil t1/2 približno 18 ur, kar kaže na ustreznost enega odmerka na dan.
Following oral administration of 1 mg/kg body weight telmisartan to cats , plasma-concentration-time curves of the parent compound are characterised by rapid absorption, with maximum plasma concentrations (Cmax) achieved after 0.5 hours (tmax).
Po peroralnem dajanju 1 mg/kg telesne mase telmisartana mačkam je za krivuljo koncentracije v plazmi po času matične spojine značilna hitra absorpcija z največjimi koncentracijami v plazmi (Cmax) doseženimi po 0,5 ure (tmax).
Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the Cmax and AUC were 20% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets.
Po peroralni uporabi 10 mg apiksabana v obliki 2 zdrobljenih 5 mg tablet s 30 g jabolčne čežane sta bili Cmax in AUC za 20 % in 16 % manjši kot po uporabi 2 celih 5 mg tablet.
Following oral administration of 14C-abiraterone acetate 1,000 mg, approximately 88% of the radioactive dose is recovered in faeces and approximately 5% in urine.
Po peroralnem vnosu 1.000 mg 14C-abirateronacetata je v blatu mogoče prestreči približno 88% radioaktivnega odmerka, v urinu pa približno 5%.
Following oral administration of 14C-abiraterone acetate as capsules, abiraterone acetate is hydrolysed to abiraterone, which then undergoes metabolism including sulphation, hydroxylation and oxidation primarily in the liver.
Po peroralnem vnosu 14C-abirateronacetata v obliki kapsul se abirateronacetat hidrolizira v abirateron, ta pa se nato večinoma v jetrih presnavlja naprej, med drugim s sulfacijo, s hidroksilacijo in z oksidacijo.
Following oral administration of 14C-labelled silodosin, the recovery of radioactivity after 7 days was approximately 33.5 % in urine and 54.9 % in faeces.
Po peroralnem vnosu s 14C-označenega silodozina je bilo po 7 dneh v urinu zaznane približno 33,5% in v fecesu približno 54,9% vnesene radioaktivnosti.
Following oral administration of 14C-laropiprant in humans, approximately 68 % of the dose was recovered in faeces (primarily as parent compound, comprising unabsorbed active substance and/or hydrolysed glucuronic acid conjugate) and 22 % was recovered in urine (primarily as metabolites).
Po peroralni uporabi 14C-laropipranta pri človeku se je 68 % odmerka pojavilo v blatu (predvsem v obliki matične snovi, vključno z neabsorbiranim zdravilom in/ali hidroliziranim konjugatom z glukuronsko kislino), 22 % pa v urinu (predvsem v obliki presnovkov).
Following oral administration of 200 mg of 14C-bupropion hydrochloride in humans, 87% and 10% of the radioactive dose were recovered in the urine and feces, respectively.
Po peroralni uporabi 200 mg 14C-bupropionijevega klorida pri človeku se je 87 % oziroma 10 % radioaktivnega odmerka izločilo z urinom oziroma blatom.
Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces.
Po peroralni aplikaciji s 14C označenega vildagliptina se je približno 85 % odmerka izločilo z urinom, 15 % odmerka pa so našli v blatu.
Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose was recovered in the faeces.
Po peroralni aplikaciji s 14C označenega vildagliptina se je približno 85 % odmerka izločilo z urinom, 15 % odmerka pa so našli v blatu.